Frontline Bevacizumab Strategies in Ovarian Cancer
Watch
Approaching a Case of Advanced Serous Ovarian Cancer
A Case of Advanced Serous Ovarian Cancer
Recurrent Ovarian Cancer: Third-Line Therapy and Beyond
Defining Rucaparib's Value in Recurrent Ovarian Cancer
Recurrent Ovarian Cancer: Selecting Second-Line Therapy
Approaching Frontline Therapy Options for Ovarian Cancer
A Case of Platinum-Sensitive Epithelial Ovarian Cancer
CLL: Combination Therapies and Future Outlook
Therapeutic Approach for CLL Progression
CLL: Rationale for Ibrutinib and Chemotherapy
Treatment Options for CLL
Risk Stratifying a Case of CLL
Treating Chronic Lymphocytic Leukemia in Elderly Patients
Case 4: Maintenance Strategies in CLL
Case 4: iFCR in Untreated CLL
Case 4: iFCG in Untreated CLL
Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy
Case 3: Therapeutic Approaches for Richter Transformation
Case 3: Progression on Ibrutinib Followed by Richter Transformation
Case 3: Response to Frontline Therapy and Toxicity Management
Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV
Case 2: Treatment Options: Venetoclax +/- Rituximab
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
Case 1: Treatment Decision: Ibrutinib Monotherapy
Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL
Case 1: Prognostic Features and Chemoimmunotherapy Treatment Options
Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL
Management of Chronic Lymphocytic Leukemia